ENTYVIO PEN

Drug Overview

ENTYVIO PEN, containing the active ingredient Vedolizumab, is a sophisticated, gut-selective therapeutic agent within the Gastroenterology field. It belongs to the Drug Class of INTEGRIN RECEPTOR ANTAGONISTS. Specifically, it is a humanized Monoclonal Antibody designed as a Targeted Therapy to manage chronic inflammation in the digestive tract. The “Pen” format refers to the pre-filled autoinjector used for Subcutaneous Maintenance for IBD (Inflammatory Bowel Disease), providing a patient-centric alternative to clinical infusions.

In the clinical landscape, the Entyvio Pen is recognized for its ability to deliver site-specific immunosuppression. Unlike systemic biologics that may dampen the immune system throughout the entire body, this medication focuses its activity within the gastrointestinal tract. In international clinical protocols established through early 2026, it is utilized to maintain long-term Mucosal Healing and clinical remission in patients with Ulcerative Colitis and Crohn’s Disease who have successfully completed their initial intravenous induction.

• Generic Name: Vedolizumab
• US Brand Names: Entyvio (Subcutaneous)
• Route of Administration: Subcutaneous (SC) Injection
• FDA Approval Status: FDA-approved for the maintenance treatment of adult patients with moderately to severely active ulcerative colitis or Crohn’s disease following intravenous induction therapy.

What Is It and How Does It Work? (Mechanism of Action)

The efficacy of the Entyvio Pen is rooted in its ability to inhibit the selective migration of pro-inflammatory white blood cells into the gut tissue, a process known as “lymphocyte trafficking.”

1. Alpha⁴ Beta⁷ Integrin Blockade

At the molecular level, Vedolizumab is a Monoclonal Antibody that specifically binds to the alpha⁴ beta⁷ integrin. This integrin is a protein expressed on the surface of certain T-lymphocytes (white blood cells) that are responsible for the chronic inflammation seen in IBD.

2. Inhibition of MAdCAM-1 Binding

To move from the bloodstream into the gut tissue, these T-cells must bind to a specific “addressin” called MAdCAM-1 (Mucosal Addressin Cell Adhesion Molecule-1). MAdCAM-1 is located primarily on the blood vessels of the gastrointestinal tract. By binding to the alpha⁴ beta⁷ integrin, the Entyvio Pen prevents these cells from “docking” with MAdCAM-1.

3. Protection of the Intestinal Epithelial Barrier

Because the medication prevents the influx of inflammatory cells into the gut wall, it stops the localized immune attack that causes ulcers and erosions. This targeted approach allows the Intestinal Epithelial Barrier to repair itself. By promoting Mucosal Healing, the medication restores the gut’s ability to act as a selective barrier, preventing the “leaky gut” phenomenon that often exacerbates IBD symptoms.

FDA-Approved Clinical Indications

Primary Indication

The primary FDA-approved use for the Entyvio Pen is:

• Subcutaneous Maintenance for IBD: Maintenance treatment of moderately to severely active Ulcerative Colitis (UC) and Crohn’s Disease (CD) in adults who have achieved a clinical response after at least two intravenous (IV) doses of vedolizumab.

Other Approved & Off-Label Uses

• Pouchitis (Off-label): Used in specialized centers to treat inflammation of the ileal pouch-anal anastomosis (IPAA) after surgery for UC.
• Refractory Microscopic Colitis (Off-label): Occasionally utilized when traditional steroids like budesonide fail to control collagenous or lymphocytic colitis.
• Checkpoint Inhibitor-Induced Colitis (Off-label): Managing severe GI side effects from cancer immunotherapies due to its gut-selective nature.

Primary Gastroenterology Indications

• Long-Term Remission Maintenance: Providing a stable, self-administered therapeutic level to prevent disease “flares.”
• Mucosal Healing Support: Sustaining the absence of visible inflammation during endoscopic evaluation (e.g., Mayo Endoscopy Score of 0 or 1).
• Steroid-Free Management: Allowing patients to remain off corticosteroids, which reduces the long-term risk of bone loss and metabolic issues.

Dosage and Administration Protocols

The Entyvio Pen is strictly for maintenance therapy. Patients must first receive two doses of Entyvio via intravenous infusion (Week 0 and Week 2) before transitioning to the pen.

Dosage Adjustments and Specific Populations

• Administration Technique: The injection should be administered in the thigh, abdomen, or upper arm. Patients must be trained by a healthcare professional on the “press-and-hold” technique required for the autoinjector.
• Missed Doses: If a dose is missed, it should be taken as soon as possible, and the 2-week schedule should be resumed from that point.
• Hepatic/Renal Impairment: No dose adjustments are required for patients with renal or hepatic insufficiency, as monoclonal antibodies are cleared through intracellular catabolism rather than traditional renal or biliary routes.
• Pediatric Use: Safety and effectiveness in pediatric patients have not been established as of 2026.

“Dosage must be individualized by a qualified healthcare professional.”

Clinical Efficacy and Research Results

Clinical trials, specifically the VISIBLE 1 (UC) and VISIBLE 2 (Crohn’s) studies, have demonstrated that subcutaneous administration is as effective as intravenous maintenance.

• Clinical Remission Rates: In the VISIBLE 1 trial for Ulcerative Colitis, 46% of patients on the 108 mg subcutaneous maintenance dose achieved clinical remission at Week 52, compared to 14% in the placebo group.
• Crohn’s Disease Efficacy: In the VISIBLE 2 trial, 48% of patients with Crohn’s Disease maintained clinical remission through one year of bi-weekly subcutaneous therapy.
• Mucosal Healing: Research (2024–2026) indicates that subcutaneous vedolizumab leads to endoscopic mucosal healing in approximately 56% of UC patients, a result equivalent to those receiving 300 mg IV every 8 weeks.
• Bioavailability and Troughs: Pharmacokinetic data shows that a 108 mg dose every 2 weeks provides steady-state “trough” levels that are sufficient to maintain near-total saturation of the alpha⁴ beta⁷ receptors in the gut.

Safety Profile and Side Effects

There are no Black Box Warnings for Entyvio or the Entyvio Pen. It is widely considered to have a superior safety profile compared to systemic TNF-alpha blockers.

Common Side Effects (>10%)

• Injection Site Reactions: Redness, itching, or swelling at the site of the needle entry.
• Nasopharyngitis: Common cold symptoms.
• Arthralgia: Joint pain.
• Headache: Usually mild and transient.

Serious Adverse Events

• Hypersensitivity Reactions: While rare with subcutaneous use, systemic allergic reactions can occur.
• Infections: There is a slight increase in the risk of upper respiratory infections and GI infections.
• Liver Injury: Rare cases of liver enzyme elevations have been reported; monitoring is standard protocol.
• PML Risk: Progressive Multifocal Leukoencephalopathy is a theoretical risk with integrin blockers, but in over a decade of clinical use, there have been no confirmed cases of PML associated with vedolizumab.

Management Strategies

Patients should rotate injection sites with every dose to prevent tissue hardening (lipohypertrophy). If an injection site reaction occurs, a cold compress can be applied. Vigilance is required regarding new-onset neurological symptoms or signs of severe infection.

Research Areas

Current Research Areas focus on “Precision Immunology” and the Gut Microbiome.

Recent research (2024–2026) is investigating the “Gut-Selective Effect” on the Gut Microbiome. Scientists are exploring if Entyvio’s ability to selectively block T-cell influx allows the Intestinal Epithelial Barrier to foster a more diverse and healthy microbial population compared to systemic biologics. There is active interest in determining if vedolizumab treatment increases the production of protective mucus layers in the colon.

Other trials are evaluating “Combination Biologic Therapy”—using the Entyvio Pen alongside other Targeted Therapies like IL-23 inhibitors for patients with “refractory” IBD. Additionally, researchers are studying the use of “Therapeutic Drug Monitoring” (TDM) specifically for the subcutaneous format to ensure that patients are not developing anti-drug antibodies that could lead to a loss of response over time.

Disclaimer: Research regarding the specific fostering of healthy microbial populations via gut-selective integrin blockade and the use of “Combination Biologic Therapy” (Entyvio + IL-23 inhibitors) for refractory IBD is currently in the investigative phase and is not yet standard clinical practice. 

Disclaimer: Research regarding the specific restoration of beneficial bacterial diversity and the “sealing” of tight junction proteins via budesonide treatment is currently in the investigative phase and is not yet standard clinical practice. 

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: Colonoscopy or fecal calprotectin to confirm response after the IV induction phase.
• Organ Function: Baseline Liver Function Tests (LFTs) and CBC.
• Specialized Testing: Screening for latent Tuberculosis (TB) and Hepatitis B is MANDATORY prior to the initial IV induction.
• Screening: Review of vaccination history. Live vaccines should be avoided once the patient starts vedolizumab.

Monitoring and Precautions

• Vigilance: Monitoring for “loss of response” which may manifest as a return of diarrhea or rectal bleeding.
• Lifestyle: Smoking cessation is critical, especially for Crohn’s patients. Patients are encouraged to follow an anti-inflammatory diet (such as the Mediterranean diet) to support Mucosal Healing.
• Storage: The Entyvio Pen must be stored in the refrigerator (2°C to 8°C). It can be kept at room temperature for up to 7 days if necessary, but must be protected from light.

“Do’s and Don’ts” List

• DO allow the pen to reach room temperature for 30 minutes before injecting to reduce discomfort.
• DO keep a diary of your injection dates and the sites used.
• DON’T shake the autoinjector, as this can damage the protein-based medicine.
• DON’T reuse a pen or needle; always dispose of them in a puncture-resistant sharps container.
• DON’T stop the medication without consulting your gastroenterologist, even if you feel 100% healthy.

Legal Disclaimer

This guide is for informational purposes only and does not replace professional medical advice, diagnosis, or treatment from a qualified healthcare provider. Always seek the advice of your physician or other qualified health practitioner with any questions you may have regarding a medical condition or the use of medications. Never disregard professional medical advice or delay in seeking it because of something you have read in this document. Information regarding clinical trials and FDA status is based on data available as of early 2026.